Literature DB >> 21324708

Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease.

Jessica A Yu1, Marvin Pomerantz, Amy Bishop, Michael J Weyant, John D Mitchell.   

Abstract

OBJECTIVE: Lady Windermere syndrome is a well-known but poorly understood female predominant phenotype of isolated right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial (NTM) infection. Despite lengthy multidrug antibiotic treatment, the presence of damaged parenchymal tissue leads to symptomatic disease recurrence, often with resistant organisms. The use of surgical resection as an adjunct to medical therapy may alter this cycle, although little is known about the use of thoracoscopic lung resection in this patient population.
METHODS: This is a retrospective review of a prospectively collected database of patients with pulmonary NTM disease from July 2004 to December 2009. All patients had focal bronchiectasis of the right middle lobe and lingula, treated with targeted antimicrobial therapy for several months prior to resection.
RESULTS: A total of 134 patients underwent 172 operations, with 38 patients having staged bilateral resections. The cohort was predominately female (96%) and Caucasian (95%), with a mean age of 59 years (range 34-81 years). Using a thoracoscopic approach in all patients, 102 middle lobectomies and 70 lingulectomies were performed. Conversion to open thoracotomy occurred in five cases (3%). Secondary procedures were performed in 20 cases (12%). There was no operative mortality. Postoperative morbidity was noted following 12 operations (7%), primarily consisting of prolonged air leak. The mean length of stay was 3.3 days (range 1-15 days).
CONCLUSIONS: Although medical therapy remains the primary treatment modality for patients with pulmonary NTM disease, the selective use of pulmonary resection may reduce the incidence of symptomatic disease recurrence. The addition of thoracoscopic resection to treatment regimens for patients with Lady Windermere syndrome can be accomplished with minimal morbidity and mortality.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21324708     DOI: 10.1016/j.ejcts.2010.12.028

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 2.  Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis.

Authors:  In Kwon Park; Kenneth N Olivier
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

3.  Treatment of Non-Tuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-11

4.  Lady Windermere Syndrome: A Very Rare Entity In Indian Medical Scenario.

Authors:  Raghavendra Rao; Shubha Sheshadri; Navin Patil; Karthik Rao; Avinash Arivazhahan
Journal:  J Clin Diagn Res       Date:  2016-01-01

5.  Characterization of Immune Cells From the Lungs of Patients With Chronic Non-Tuberculous Mycobacteria or Pseudomonas aeruginosa Infection.

Authors:  Alan R Schenkel; John D Mitchell; Carlyne D Cool; Xiyuan Bai; Steve Groshong; Tilman Koelsch; Deepshikha Verma; Diane Ordway; Edward D Chan
Journal:  Immune Netw       Date:  2022-04-11       Impact factor: 5.851

Review 6.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

Review 7.  Nontuberculous mycobacterial pulmonary infections.

Authors:  Margaret M Johnson; John A Odell
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

8.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

9.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

10.  Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease.

Authors:  Hyung Koo Kang; Hye Yun Park; Dohun Kim; Byeong-Ho Jeong; Kyeongman Jeon; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Won-Jung Koh
Journal:  BMC Infect Dis       Date:  2015-02-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.